1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Verapamil |
| brand | String | Calan, Calan SR, Verelan, Verelan PM, Isoptin SR |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Calcium_channel_blockers|Calcium channel blocker (non-dihydropyridine)]] • [[:Category:Antianginals|Antianginal]] • [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]] • [[:Category:Antihypertensives|Antihypertensive]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000A66-QINU`"', '"`UNIQ--vote-00000A67-QINU`"', '"`UNIQ--vote-00000A68-QINU`"', '"`UNIQ--vote-00000A69-QINU`"', '"`UNIQ--vote-00000A6A-QINU`"' |
| starting_dose | String | IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses |
| preparations | String | IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL |
| fda_max | String | ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral (IR and multiple ER) • IV |
| onset | String | IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours |
| duration | String | IR: 6-8 hours; ER: 24 hours |
| halflife | String | 3-7 hours (IR); functional 24 hours (ER)'"`UNIQ--ref-00000A6B-QINU`"' |
| bioavailability | String | ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' |
| pregnancy | String | Limited data; alternative antihypertensives generally preferred. Crosses placenta.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
